Respiratory Syncytial Virus Infection in Neonatal Intensive Care Units Throughout Turkey: Prospective Multicenter Study (TurkNICU-RSV Trial)

Management of Hospitalized Respiratory Syncytial Virus (RSV) Infected Patients in the Neonatal Intensive Care Unit (NICU) and Control of Epidemics; TurkNICU-RSV Study: A Multicentric, Prospective Trial

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01915394

Acronym

TurkNICU-RSV

Enrollment

250

Registered

2013-08-02

Start date

2013-09-30

Completion date

2014-06-30

Last updated

2015-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infections, Epidemics, Respiratory Syncytial Virus Infections

Keywords

Respiratory Syncytial Virus Infections, Epidemics, Neonatal Intensive Care Unit, Newborn infants

Brief summary

The principle purpose of this multicenter trial is to determine the definition, timing and the percentage of nosocomial RSV epidemics throughout Turkey. In addition, secondary purpose of the trial is to determine the prevention strategies of further spread of Respiratory Syncytial Virus (RSV) in the neonatal intensive care unit (NICU).

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

5 Days to 90 Days

Healthy volunteers

Inclusion criteria

* Confirmed RSV infection with either RSV-strip test or polymerase chain reaction (PCR). * Admission to the NICU or hospitalized in the NICU between 1 October 2013 and 01 April 2014.

Exclusion criteria

* Refused informed consent

Design outcomes

Primary

Measure	Time frame
Hospitalized Respiratory Syncytial Virus infected Newborn in the Neonatal Intensive Care Units, and its relation with possible epidemics.	Patients will be followed during hospitalization, with expected average of 3 weeks

Secondary

Measure	Time frame	Description
Mortality	Patients will be followed during hospitalization, with expected average of 3 weeks	mortality related to RSV infection and epidemics

Countries

Turkey (Türkiye)

Outcome results